TABLE 3

Primary diagnoses for the ME population

Clinical diagnosisn (%) with diagnosis by treatment groupa
250 mg REL + IMI (n = 83)125 mg REL + IMI (n = 87)Placebo + IMI (n = 85)Total (n = 255)
Complicated appendicitis44 (53.0)47 (54.0)43 (50.6)134 (52.5)
    Perforation22 (26.5)23 (26.4)20 (23.5)65 (25.5)
    Periappendiceal abscess22 (26.5)24 (27.6)23 (27.1)69 (27.1)
Diverticular abscess5 (6.0)2 (2.3)5 (5.9)12 (4.7)
Complicated cholecystitis14 (16.9)15 (17.2)13 (15.3)42 (16.5)
    Gangrenous9 (10.8)9 (10.3)8 (9.4)26 (10.2)
    Perforation1 (1.2)2 (2.3)3 (3.5)6 (2.4)
    Progression beyond gallbladder wall4 (4.8)4 (4.6)2 (2.4)10 (3.9)
Perforated hollow viscus8 (9.6)9 (10.3)12 (14.1)29 (11.4)
    Stomach4 (4.8)1 (1.1)3 (3.5)8 (3.1)
    Duodenum1 (1.2)5 (5.7)2 (2.4)8 (3.1)
    Jejunum/ileum0 (0.0)1 (1.1)2 (2.4)3 (1.2)
    Colon3 (3.6)2 (2.3)5 (5.9)10 (3.9)
Peritonitis3 (3.6)1 (1.1)0 (0.0)4 (1.6)
    Posttraumatic1 (1.2)0 (0.0)0 (0.0)1 (0.4)
    Postsurgical2 (2.4)1 (1.1)0 (0.0)3 (1.2)
Intra-abdominal abscess2 (2.4)3 (3.4)3 (3.5)8 (3.1)
    Liver2 (2.4)2 (2.3)3 (3.5)7 (2.7)
    Splenic0 (0.0)1 (1.1)0 (0.0)1 (0.4)
Multiple abscesses2 (2.4)2 (2.3)3 (3.5)7 (2.7)
Other5 (6.0)8 (9.2)6 (7.1)19 (7.5)
Postoperative infection3 (3.6)6 (6.9)5 (5.9)14 (5.5)
  • a REL, relebactam; IMI, 500 mg imipenem-cilastatin.